Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab plus fludarabine/cyclophosphamide at standard versus mega dose in relapsed or previously treated chronic lymphocytic leukemia
ISRCTN51382468Phase 2Completed
- Sponsor
- Leeds Teaching Hospitals NHS Trust
- Start
- Jan 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of ofatumumab, fludarabine and cyclophosphamide in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Leeds Teaching Hospitals NHS Trust. Primary endpoint: Complete response rate. Started Jan 2012; status: completed.
02
Drugs
ofatumumabfludarabinecyclophosphamide
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ISRCTN51382468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN51382468.